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Abstract
Background: Congenital central hypoventilation syn-
drome (CCHS) is a rare disorder of autonomic control. A 
hypoglycaemic seizure in a 4-year-old girl with CCHS led 
to a more detailed examination of glycaemic control in a 
cohort of children with CCHS.
Methods: We conducted an observational cohort study 
of glucose homeostasis in seven children (3  months to 
12  years) with genetically confirmed CCHS using a com-
bination of continuous glucose monitoring (CGM), fasting 
studies and oral glucose tolerance test (OGTT). CGM was 
used to compare the effect of diazoxide and dietary inter-
vention in the index patient.
Results: Hypoglycaemia was not elicited by fasting in 
any of the patients. Increased postprandial glycaemic 
variability was evident in all patients using CGM, with 
seven of seven patients demonstrating initial postpran-
dial hyperglycaemia (plasma-glucose concentration 
>7.8  mmol/L), followed by asymptomatic hypoglycae-
mia (plasma- glucose concentration ≤2.8  mmol/L) in two 
of seven patients that was also demonstrated on OGTT. 
Both diazoxide and low Glycaemic Index (GI) dietary 
intervention reduced the proportion of CGM readings 
<4 mmol/L; however, diazoxide also increased the propor-
tion of readings in the hyperglycaemic range.
Conclusions: Glucose variability associated with auto-
nomic dysfunction may be unrecognised in CCHS, par-
ticularly in children with more severe phenotypes. This 
report highlights the occurrence of hyperglycaemia as 
well as hypoglycaemia in CCHS. Given the challenges of 
recognising hypoglycaemia based on clinical symptom-
atology, the use of CGM may facilitate its identification 
allowing appropriate management. The observed nor-
moglycaemia during fasting combined with increased 
postprandial plasma blood glucose level (BGL) vari-
ability is more consistent with dumping syndrome than 
persistent hyperinsulinism. Dietary modifications there-
fore may be more effective than diazoxide in managing 
hypoglycaemia.
Keywords: congenital central hypoventilation syndrome; 
diazoxide; hyperglycaemia; hyperinsulinism; hypoglycae-
mia; seizures.
Introduction
Congenital central hypoventilation syndrome (CCHS) is a 
rare neurocristopathy resulting from heterozygous poly-
alanine repeat expansions within the paired-like home-
obox 2B (PHOX2B) gene [1]. The main symptom is alveolar 
hypoventilation resulting from an inappropriate central 
respiratory drive. Patients with the most severe pheno-
type, which often includes features of autonomic nervous 
system dysfunction (ANSD) [2], generally have a higher 
number of polyalanine repeats [3–5].
Dysregulated glucose homeostasis may rep-
resent an under-appreciated component of CCHS. 
Initial case reports described hypoglycaemia occur-
ring in the context of hyperinsulinism [6–11]. A recent 
study, however, suggested a more complex disorder 
of glucose regulation, describing hyperglycaemia in 
both the fasting and postprandial state [12]. Out of 14 
patients studied, using 24-h plasma glucose profiles and 
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responses to an oral glucose tolerance test (OGTT), 57% 
were found to have an abnormality of glucose homeo-
stasis. Interestingly, none of the patients exhibited 
hypoglycaemia after an overnight fast [12]. The results of 
continuous glucose monitoring (CGM) was first reported 
in an infant (PHOX2B 20/27) with symptomatic postpran-
dial hypoglycaemia [9]. Although hyperglycaemia was 
not the subject of this paper, the patient’s CGM traces 
demonstrated immediate postprandial glycaemic excur-
sions up to 11.1 mmol/L (200 mg/dL) followed by asymp-
tomatic hypoglycaemia (~2.2  mmol/L) occurring prior 
to dietary or medical intervention [9]. These findings 
highlighted the possibility of a dynamic disturbance of 
glycaemic regulation in CCHS.
The autonomic nervous system (ANS) coordinates the 
function of pancreatic islets, with parasympathetic acti-
vation stimulating both insulin and glucagon secretion, 
while the sympathetic nervous system inhibits insulin 
secretion while promoting glucagon release. Disturbances 
in the oscillatory patterns of insulin secretion have been 
described in association with diseases affecting the ANS 
[13]. Abnormal gastrointestinal motility associated with 
ANSD may also result in altered glucose delivery across 
the gut thereby contributing to glycaemic variability [14]. 
Patients with dumping syndrome have early postpran-
dial hyperglycaemia that triggers an exaggerated insulin 
response resulting in subsequent postprandial hypogly-
caemia [14].
The occurrence of an unprovoked, hypoglycaemic 
seizure occurring 2–3  h following a meal in a 4-year-old 
girl (PT1) with CCHS prompted a more detailed evaluation 
of glucose homeostasis in a cohort of seven children with 
CCHS. We postulated that a disconnect between insulin 
release and plasma blood glucose level (BGL) second-
ary to ANSD may contribute to both hyperglycaemia and 
hypoglycaemia in these patients.
Patients and methods
Subjects
All children with CCHS managed by the respiratory department of the 
Lady Cilento Children’s Hospital, Brisbane, Australia, were invited to 
participate in a cross-sectional descriptive study. The diagnosis of 
CCHS was based on the following criteria: (1) persistent central alveo-
lar hypoventilation in the absence of primary lung, neuromuscular, 
cardiac or brain stem abnormality, (2) absent or weak hypercapnic 
ventilatory responses and (3) a confirmed genetic diagnosis of CCHS 
in keeping with the official clinical policy statement of the American 
Thoracic Society [4]. In total, eight patients with CCHS were screened 
between 2016 and 2017. One patient (PHOX2B 20/24), with significant 
autistic spectrum disorder but without other ANSD was excluded as 
they were unable to tolerate CGM. PT1  was diagnosed at 2  months 
of age while all other patients were diagnosed within the neonatal 
period upon investigation of hypoventilation. Only PT1 had features 
of ANSD. Patient characteristics are shown in Table 1.
CGM
Both inpatient and outpatient CGM were undertaken in PT1 and 
PT2. Outpatient CGM screening was undertaken in PT3 to PT7 for 
5 days while children performed their normal daily activities using 
the Dexcom™ G4 Continuous Glucose Monitoring System (San 
Diego, CA, USA). Outpatient monitoring was more representative 
of a daily glycaemic profile and provided the opportunity to moni-
tor patients for a longer period of time. As all children in the study 
required intensive respiratory support, outpatient monitoring also 
avoided the practical difficulties associated with extended inpa-
tient monitoring.
None of the children experienced any intercurrent illnesses dur-
ing their CGM monitoring. Patients were asked to calibrate the CGM 
measurements at least twice daily, and to validate any hypoglycae-
mia or hyperglycaemia using glucometer readings (FreeStyle Optium 
Neo Blood Glucose and Ketone Monitoring System, Abbott Diabetes 
Care Inc., Alameda, CA, USA). Patients maintained a food diary dur-
ing the entire period of screening. A single paediatric endocrine dieti-
cian provided education and monitoring of all food diaries.
Table 1: Clinical characteristics of participants.
  Age, sex   Genotypea  Respiratory 
support
  Cardiac 
dysautonomia
  CNS disorders   GI dysmotility   Neural crest 
tumours
PT1   4 years, female   20/28  Sleep-Trach  Yesb   No   Yese   No
PT2   1 year, female   20/24  Sleep-Trach  No   No   No   No
PT3   10 years, female   20/24  Sleep-NIV   No   No   No   No
PT4   9 years, male   20/24  Sleep-NIV   No   No   No   No
PT5   5 years, male   20/24  Sleep-Trach  No   Yesc   No   No
PT6   8 years, female   20/25  Sleep-NIV   No   Yesc,d   No   No
PT7   3 month, female   20/24  Sleep-Trach  No   No   No   No
aNumber of polyalanine repeats. bCardiac pacemaker. cSpeech delay. dAutistic spectrum disorder. eHirschsprung’s disease. Trach, 
tracheostomy; NIV, non-invasive ventilation; GI, gastrointestinal.
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Comparison of diazoxide and dietary intervention on 
glycaemic variability
PT1  had additional CGM to compare the effects of diazoxide treat-
ment and dietary intervention on plasma glucose levels. CGM profiles 
were obtained for 48 h immediately prior to starting diazoxide, dur-
ing the last 48 h of a 7-day course of diazoxide treatment (10 mg/kg/
day) and for the last 48 h of a dietary intervention that began 8 days 
after ceasing diazoxide. This dose of diazoxide was chosen because 
it is commonly used as a starting dose in the treatment of childhood 
hyperinsulinism and higher doses are associated with the risk of seri-
ous adverse effects. The dietary intervention consisted of restricting 
high Glycaemic Index (GI) carbohydrates (simple sugars) in prefer-
ence for low GI (complex) carbohydrates only.
Fasting studies
Patients who displayed hypoglycaemia on CGM (PT1 and PT2) under-
went an inpatient fasting study (20  h for PT1; 12  h for PT2). The 
remaining patients had a plasma glucose and insulin measurement 
after an overnight fast at home.
Oral glucose tolerance test
A standard OGTT was conducted in two patients (PT1 and PT2) who 
had evidence of hypoglycaemia during CGM screening. This involved 
ingestion of a glucose solution containing 1.75 g glucose/kg of body 
weight within 5 min [15]. Blood samples for glucose and insulin were 
collected at baseline, 30, 60, 90 and 120 min [15].
Definitions
Hypoglycaemia was defined as a plasma glucose concentration of 
≤2.8 mmol/L [16] and to be “postprandial” if occurring within 2–4 h 
after a meal. Postprandial hyperglycaemia was defined as a plasma 
glucose concentration of >7.8  mmol/L within the first 2  h after a 
meal [17–20]. Normal glucose tolerance after an OGTT was defined 
as a plasma glucose concentration of <7.8 mmol/L at 120 min, with 
glucose intolerance defined as a plasma glucose concentration of 
7.8–11.0 mmol/L at 120 min [21].
The study was approved by the Children’s Health Queens-
land Hospital and Health Service Human Research Ethics Commit-
tee (HREC reference number 17/QRCH/233). Informed consent was 
obtained from parents or legal guardians.
Assays
Insulin was measured by a simultaneous one-step immunoenzy-
matic assay with limit of detection (LOD) = 0.03 mU/L, and glucose 
by oxygen rate assay with LOD = 0.2 mmol/L (Beckman Coulter Syn-
chron Clinical Systems, NY, USA).
Results
Spontaneous symptomatic hypoglycaemia
PT1 presented with a spontaneous hypoglycaemic 
seizure  (plasma glucose 2.7  mmol/L) at the age of 
4 years, 2–3 h after her typical evening meal. She was 
not suffering from an intercurrent illness at the time. 
Urinary ketones were not detected and a robust corti-
sol response was demonstrated (cortisol 946 mmol/L), 
but unfortunately information on other counter-reg-
ulatory hormones was not available. Intramuscu-
lar Glucagon 0.5  mg initially increased her plasma 
glucose to 3.1 mmol/L but she required an intravenous 
10% dextrose bolus (2  mL/kg) followed by a mainte-
nance infusion (4  mg/kg/min glucose infusion rate) 
for 6  h to maintain normoglycaemia and improve her 
conscious state. An asymptomatic hypoglycaemic 
episode (plasma glucose 1.8  mmol/L) requiring oral 
treatment had occurred during an episode of gastro-
enteritis 4 months prior but had not been investigated. 
PT1 also underwent additional inpatient investiga-
tions to exclude non- endocrine causes of a seizure, 
including  polysomnography, echocardiography and 
 electroencephalogram. Previous episodes of hypogly-
caemia had not been documented in the other patients 
with CCHS.
Fasting study
PT1 and PT2 demonstrated normal plasma glucose con-
centrations during fasting studies conducted in the hospi-
tal (Table 2) and after an overnight fast prior to an OGTT. 
The other patients with CCHS also had normal plasma 
glucose levels after outpatient overnight fasting for at 
least 12 h (4.1–5.3 mmol/L).
Continuous glucose monitoring
Asymptomatic postprandial hypoglycaemia validated by 
glucometer readings (2.1 mmol/L and 2.5 mmol/L, respec-
tively) was detected in PT1 and PT2, occurring 2–4 h fol-
lowing typical meals (Table 3, Figure 1). Postprandial 
hyperglycaemia (8.3–16.7 mmol/L) was also demonstrated 
1–2 h following meals in all seven patients, with validation 
by glucometer testing (Table 3).
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Oral glucose tolerance test
PT1 and PT2 underwent an OGTT that demonstrated 
asymptomatic non-ketotic hypoglycaemia at 120  min 
in the presence of detectable insulin levels (Table 4). 
PT2 displayed initial hyperglycaemia (plasma glucose 
10.1 mmol/L at 60 min).
Intervention
A low GI dietary intervention was associated with a reduc-
tion in the proportion of CGM readings <4 mmol/L when 
compared with baseline (4% versus 11%), without having 
an obvious effect on the proportion of CGM readings 
above 8  mmol/L (4% versus 3%). Diazoxide (10  mg/kg/
day) treatment was also associated with a slight reduction 
in the proportion of CGM readings <4 mmol/L when com-
pared with baseline (9% versus 11%); however, the pro-
portion of CGM readings above 8 mmol/L increased (15% 
versus 3%) (Table 5, Figure 1).
Discussion
The presented data suggests that postprandial glycaemic 
variability, particularly hyperglycaemia, is common in 
CCHS. Hypoglycaemia also occurs, but is less frequent 
than hyperglycaemia and may be unrecognised in CCHS 
due to the absence of typical clinical features associated 
with hypoglycaemia. CGM appears to be more sensitive 
than formal fasting studies for evaluating hypoglycaemic 
risk, as the episodes of hypoglycaemia tend to occur after 
a meal. The postprandial glycaemic fluctuations com-
bined with the absence of fasting induced hypoglycaemia 
are more consistent with dumping syndrome rather than 
persistent hyperinsulinism. As such, dietary interventions 
should be considered as an alternative to diazoxide for the 
initial management of hypoglycaemia in CCHS.
Meissner et al. first described the occurrence of hypo-
glycaemia in association with CCHS, with similar cases 
subsequently reported (Table 6). Episodes of hypoglycae-
mia often occurred postprandially rather than in response 
to fasting [8, 9]. In the only other report describing post-
prandial hyperglycaemia in patients (aged 2  months 
to 18  years) with CCHS, indices of insulin resistance 
Table 3: Summary of postprandial glucose fluctuations using 
continuous glucose monitoring (CGM).
  CGM
Postprandial 
glucosea peak, 
mmol/L
  Postprandial 
glucoseb nadir, 
mmol/L
PT1   8.3   2.2
PT2   9.3   2.4
PT3   11.1   3.8
PT4   8.4   4.0
PT5   16.7   4.4
PT6   8.0   3.3
PT7   10.3   3.3
aPeak levels 1–2 h postprandially. bNadir levels 2–4 h postprandially. 
Hypoglycaemia = plasma BGL ≤2.8 mmol/L [16]. Hypoglycaemia is 
recorded to be “postprandial” if occurring within 2–4 h after a meal. 
Postprandial hyperglycaemia = plasma BGL >7.8 mmol/L within first 
2 h after a meal [17–20].
Table 4: Oral glucose tolerance test.
  Time, 
min
  BGLa, 
mmol/L
  Insulin, 
mU/L
  Acylcarnitine
profile
  BOHBb, 
mmol/L
  FFAc, 
mmol/L
PT 1   0   3.6     Normal    
  60   5.7        
  120   2.2   2.4     0.27   0.57
PT 2   0   5.6     Normal    
  60   10.1        
  120   2.6   1.1     0.11  
aBGL, blood glucose level. bBOHB, beta hydroxy butyrate 
(<1.1 mmol/L). cFFA, free fatty acids (0.1–0.6 mmol/L). OGTT 
performed with prescription of 1.75 g of glucose/kg of body 
weight (maximum of 75 g) consumed <5 min. Normal glucose 
tolerance = plasma BGL <7.8 mmol/L at 120 min. Glucose 
intolerance = plasma BGL 7.8–11.0 mmol/L at 120 min [21].
Table 2: Summary of findings from fasting study.
 
 
Inpatient formal fasting study
Duration   BGLa nadir, mmol/L   Final BGLa, mmol/L   Insulin, mU/L   FFAb, mmol/L
PT1   20 h   3.0   4.2   1.4   1
PT2   12 h   3.1   3.1   1.3   1.2
aBGL, blood glucose level. bFFA, free fatty acids (0.1–0.6 mmol/L). Insulin and FFA measured at plasma BGL nadir.
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and secretion were interestingly normal. In this cohort, 
hypoglycaemia was not induced by fasting, neither was 
it detected following an OGTT or after meals [12]. The 
discrepancy between our findings with regard to post-
prandial or OGTT-induced hypoglycaemia and those of 
the previous study may result from a number of factors. 
Methodological issues with regard to plasma glucose 
monitoring (CGM versus plasma glucose) or whether the 
glycaemic response was evaluated after normal meals or 
during an OGTT need to be considered. In addition, the 
definitions of “hyperglycaemia” and “hypoglycaemia” 
may vary slightly between studies. We applied definitions 
outlined by the International Diabetes Federation Clini-
cal Guidelines Task Force and Lang et  al., respectively 
[16, 20]. Another aspect to consider is the effect of age 
on the risk of hypoglycaemia, as the natural history may 
change over time. Our cohort and other cases reported in 
the literature, are generally younger than those studied by 
Gelwane et al. who did not report hypoglycaemia [12].
Recognising hypoglycaemia is particularly challeng-
ing in children with CCHS, as indicated by the frequency 
of seizure at first presentation (Table 6). With the excep-
tion of the hypoglycaemic seizure in PT1, there was no 
correlation between symptoms typically ascribed to 
hypoglycaemia (diaphoresis, pallor and tremor) and low 
plasma glucose levels in our cohort. Patients with CCHS 
frequently experience such symptoms at plasma glucose 
levels >4  mmol/L, which often resolve with increased 
respiratory support indicating that these symptoms may 
be attributable to a deterioration in gas exchange from 
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Figure 1: Continuous glucose monitor profile.
Continuous glucose monitoring (CGM) (PT1) over (A) 48 h at baseline, immediately prior to diazoxide. Episodes of postprandial 
hyperglycaemia followed by asymptomatic hypoglycaemia or trend towards low plasma blood glucose levels (BGLs) were observed following 
high GI meals in particular. (B) The final 48 h of a 7-day snapshot of diazoxide therapy, demonstrating fewer episodes of postprandial 
hypoglycaemia during diazoxide therapy, but with a plasma BGL nadir similar to baseline. There was an upward shift in the average plasma 
BGL and a greater degree of hyperglycaemia. (C) The final 48 h of an 8-day period of dietary intervention only, which allowed for diazoxide 
“washout” (8 days post diazoxide cessation). A low GI diet provided greater protection against postprandial hypoglycaemic events without 
increasing the risk of hyperglycaemia, compared to baseline.
Table 5: Continuous glucose monitor metrics.
Plasma blood glucose level   (A) Baseline  (B) Diazoxide  (C) Low GIa diet only
Highest value, mmol/L   8.3  11.7  9.7
Lowest value, mmol/L   2.2  2.3  2.2
Period average, mmol/L   4.6  6.2  5.4
Values >7.8 mmol/L   3%  15%  4%
Values 4–8 mmol/L   86%  76%  92%
Values <2.8 mmol/L   11%  9%  4%
aGI, Glycaemic Index.
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under-ventilation. This highlights the importance of 
having a sensitive screening strategy for detecting hypo-
glycaemic risk, such as CGM. It would appear from the 
current findings and previous studies that formal fasting 
is unlikely to be useful in identifying patients at risk of 
hypoglycaemia. It is unclear whether unrecognised hypo-
glycaemia contributes to reduced neurocognitive perfor-
mance in CCHS but the available evidence highlights the 
need to develop a screening strategy aimed at identifying 
hypoglycaemic risk in these children. Patients with gly-
caemic disturbance reported thus far harbour six or more 
alanine repeat expansions. Given that there is a geno-
type-phenotype correlation observed in other features of 
CCHS, the severity of glycaemic dysregulation may also be 
anticipated by the genotype. The limited evidence thus far 
supports initially screening the high-risk group, defined 
according to age (<3 years), polyalanine repeat length (≥27 
repeats) and the presence of ANSD [4]. CGM is likely to be 
more sensitive in detecting hypoglycaemia than formal 
fasting studies in CCHS, with its utility demonstrated 
in other disorders which result in similar postprandial 
glucose excursions [22].
Hypoglycaemia in CCHS has been ascribed to hyperin-
sulinism and therapeutic strategies have included dietary 
interventions and medications aimed at reducing insulin 
release (Tables 4 and 6). Diazoxide treatment in our 
patient was associated with a decrease in the proportion 
of hypoglycaemic readings. However, the mean plasma 
glucose concentration and the proportion of hyperglycae-
mic readings were increased, similar to previous reports 
(Table 6). Compared to diazoxide, the dietary interven-
tion achieved a greater reduction in glucose readings less 
than 4 mmol/L, while at the same time increasing the pro-
portion of readings in the target range. Previous studies 
have also reported improved hypoglycaemia with dietary 
interventions in all but one case [9]. Given that diazoxide 
treatment is associated with a range of other side-effects 
in addition to hyperglycaemia [23, 24], it would seem rea-
sonable to consider a dietary intervention as a first step 
before commencing diazoxide.
While the mechanisms underlying glycaemic dys-
regulation in CCHS are not well understood, the initial 
hyperglycaemia followed by hypoglycaemia after a meal 
indicates a temporal disconnection between the plasma 
glucose level and the insulin response. The complex 
neural and humoral control of glucose homeostasis, and 
the central role that PHOX2B plays in the ANS, raises the 
possibility that there are multiple defects in glycaemic 
control in CCHS. The inappropriately normal or frankly 
elevated insulin level at the time of hypoglycaemia may 
represent an imbalance between the inhibitory action of 
the sympathetic system and the stimulatory action of the 
parasympathetic system. Dysregulated insulin secretion 
has also been reported in other conditions with ANSD, 
such as dopamine beta-hydroxylase (DBH) deficiency. 
DBH null (DBH−/−) mice experience hyperinsulinaemia 
associated with loss of inhibitory sympathetic tone com-
bined with increased parasympathetic tone [25]. Although 
DBH-deficient humans also have episodic hypoglycaemia, 
it is not yet clear if this is related to hyperinsulinaemia [26]. 
Interestingly, PHOX2B is an important regulator of DBH, 
and PHOX2B mutations lead to impaired transactivation of 
the DBH promoter [27]. A rapid delivery of glucose across 
the gastrointestinal tract may also be contributing to the 
postprandial glycaemic variability in CCHS. Dumping 
syndrome describes the rapid absorption of carbohydrate 
after a meal resulting in early hyperglycaemia, followed 
by an exaggerated glucagon-like peptide-1 (GLP-1) depend-
ent insulin surge [28, 29]. Abnormal glucose homeostasis 
related to gut dysfunction has been described in a case 
series of children with dumping syndrome, including one 
child with CCHS, Hirschsprung’s disease and generalised 
ANSD [14]. Hormonal analyses showed an exaggerated 
release of insulin resulting in a rapid fall in glucose. An 
inadequate glucagon response may also contribute to the 
persistence of hypoglycaemia after the decline in circulat-
ing insulin to undetectable levels. GLP-1 is defined as an 
“incretin” based on its ability to enhance glucose-induced 
insulin secretion in response to a meal [30–32], and has 
other actions that complement the incretin effect, includ-
ing inhibition of glucagon secretion [33]. GLP-1 receptor 
blockers have been shown to reduce insulin secretion 
[28, 34, 35] and prevent hypoglycaemia in patients suffer-
ing from postprandial hypoglycaemia following gastric 
bypass surgery. The ANSD seen in CCHS could be influ-
encing both glucose delivery (gut function) and glucose 
disposal (insulin secretion). It would be of interest to 
compare glycaemic variability after an intravenous versus 
an oral glucose load, and to measure postprandial GLP-1 
levels in children with CCHS.
The current study is subject to some limitations 
given the relatively small sample size, with the major-
ity of patients having mild PHOX2B mutations. Within 
our cohort, we observed that glycaemic dysregulation 
was most profound in the patient (PT1) with the highest 
number of polyalanine repeat expansions, and the most 
severe phenotype that included ANSD. Given that five of 
seven patients had an identical and relatively mild geno-
type (PHOX2B 20/24), our study was not able to examine 
whether there is a genotype-phenotype correlation with 
regard to glycaemic variability. Additionally, our patient’s 
medical and psychosocial needs posed challenges with 
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regard to undertaking more detailed metabolic assess-
ments, including continuous inpatient blood glucose 
measurements. The comparison between the effects of 
diazoxide treatment and dietary intervention on glycae-
mic variability was also only assessed in one patient and 
requires further evaluation in a larger cohort with detailed 
recording of dietary intake. Finally, although CGM pro-
vides potential benefits relative to episodic plasma glucose 
measurements in detecting dynamic glucose profiles, it is 
still a maturing technology [36].
Conclusions
Glucose variability may be unrecognised in CCHS, par-
ticularly in children with features of ANSD. This report 
highlights the occurrence of hyperglycaemia as well as 
hypoglycaemia in CCHS. Given the challenges of recog-
nising hypoglycaemia based on clinical symptomatology, 
and the fact that it commonly occurs post-prandially, 
CGM may be a useful strategy to screen for hypoglycae-
mia. The observed normoglycaemia during fasting with 
increased postprandial plasma glucose variability is con-
sistent with a dynamic abnormality in glucose control 
rather than persistent hyperinsulinism. ANSD is likely 
to be impairing the responses that normally co-ordinate 
glucose delivery across the gut and peripheral insulin 
mediated glucose disposal. Therefore, dietary modifica-
tions may be more effective than diazoxide in managing 
hypoglycaemia. The long-term consequences and the 
natural history of dys regulated glucose homeostasis in 
CCHS are unknown.
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